Table 5.
Median dose and relative confidential interval values of EGFR/HER2 pathway inhibitors on BTC cell lines.
| TFK1 | EGI-1 | HuH28 | TGBC1-TKB | |
|---|---|---|---|---|
| Erlotinib Dm (CI) | 2.59 μM | 5.72 μM | >10 | >10 |
| (0.17-3.46) | (1.9-7.5) | |||
| Gefitinib Dm (CI) | 1.8 μM | 2.48 μM | >10 | >10 |
| (1.1-2.9) | (1.5-4.03) | |||
| Lapatinib Dm (CI) | 5.25 μM | 4.02 μM | 2.02 μM | >10 |
| (1.01-7.2) | (1.01-5.9) | (1.2-4.62) | ||
| Sorafenib Dm (CI) | 6.2 μM | 2.06 μM | >10 | 5.9 μM |
| (3.1-12.4) | (0.45-9.37) | (3.8-7.9) | ||
| Everolimus Dm (CI) | 0.20 μM | 0.5 μM | >10 | 0.42 μM |
| (0.02-1.76) | (0.1-1.5) | (0.33-0.54) | ||
The Median doses (Dm) and relative confidential interval (CI) of targeted therapies which affected 50% proliferation on the four cell lines (TFK1, EGI-1, HuH28, and TGBC1-TKB) were calculated after 72 hrs of drug treatment.